Presence of CMTM6 augmented T cell inhibitory capacity of PD-L1-expressing tumor cells, whereas CMTM6 depletion mitigated the attenuation of tumor-specific T cell activity both in vitro and in vivo. This evidence concerns the gene CD274 and neoplasm.